Clinical Trial Update: Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Nanatinostat with valganciclovir (and in combination with pembrolizumab) for EBV-positive solid tumors, including nasopharynge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Gastric Cancer
• Epstein-barr Virus-associated Leiomyosarcoma
• Epstein-barr Virus-associated Sarcoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• Nanatinostat (nanatinostat)
• Pembrolizumab (pembrolizumab)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Viracta Therapeutics, Inc. | Conditions: Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2025-02-24